Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The Sensitivity and Specificity of Touch Preparation for Rapid Diagnosis of Invasive Fungal Sinusitis: A Pilot Study.

Schuman TA, Nguyen JH, Yelverton JC, Almenara JA, Powers CN.

Ear Nose Throat J. 2019 Jun 2:145561319840853. doi: 10.1177/0145561319840853. [Epub ahead of print]

PMID:
31155939
2.

The sensitivity and specificity of touch preparation for rapid diagnosis of invasive fungal sinusitis: A pilot study.

Schuman TA, Nguyen JH, Yelverton JC, Almenara JA, Powers CN.

Ear Nose Throat J. 2018 Jan-Feb;97(1-2):E32-E36.

PMID:
29493729
3.

Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway.

Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S.

J Biol Chem. 2016 Aug 19;291(34):17535. doi: 10.1074/jbc.A109.095208. No abstract available.

4.

Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.

Dumur CI, Almenara JA, Powers CN, Ferreira-Gonzalez A.

Diagn Pathol. 2015 Sep 17;10:169. doi: 10.1186/s13000-015-0403-0.

5.

Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.

Sirica AE, Almenara JA, Li C.

Exp Mol Pathol. 2014 Dec;97(3):515-24. doi: 10.1016/j.yexmp.2014.10.007. Epub 2014 Oct 28. Review.

6.

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, Grant S.

Blood. 2011 Nov 10;118(19):5189-200. doi: 10.1182/blood-2011-02-339432. Epub 2011 Sep 12.

7.

Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.

Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S.

Blood. 2011 Feb 10;117(6):1947-57. doi: 10.1182/blood-2010-06-291146. Epub 2010 Dec 10.

8.

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.

Zhang Z, Oyesanya RA, Campbell DJ, Almenara JA, Dewitt JL, Sirica AE.

Hepatology. 2010 Sep;52(3):975-86. doi: 10.1002/hep.23773.

PMID:
20607690
9.

Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.

Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S.

J Biol Chem. 2010 Mar 26;285(13):10064-77. doi: 10.1074/jbc.M109.095208. Epub 2010 Jan 11. Retraction in: J Biol Chem. 2016 Aug 19;291(34):17535.

10.

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Sirica AE, Dumur CI, Campbell DJ, Almenara JA, Ogunwobi OO, Dewitt JL.

Clin Gastroenterol Hepatol. 2009 Nov;7(11 Suppl):S68-78. doi: 10.1016/j.cgh.2009.08.023. Review.

11.

Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts.

Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, Zipkin RE, Dent P, Kordula T, Milstien S, Spiegel S.

Cancer Res. 2009 Sep 1;69(17):6915-23. doi: 10.1158/0008-5472.CAN-09-0664.

12.

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, Grant S.

Mol Cancer Ther. 2008 Oct;7(10):3285-97. doi: 10.1158/1535-7163.MCT-08-0385.

13.

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, Grant S.

Blood. 2008 Sep 15;112(6):2439-49. doi: 10.1182/blood-2008-05-159392. Epub 2008 Jul 9.

14.

A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.

Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S, Spiegel S.

Blood. 2008 Aug 15;112(4):1382-91. doi: 10.1182/blood-2008-02-138958. Epub 2008 May 29.

16.

Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.

Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Giménez MS, Dent P, Grant S.

Mol Cancer Ther. 2007 Feb;6(2):692-702.

17.

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.

Rosato RR, Almenara JA, Maggio SC, Atadja P, Craig R, Vrana J, Dent P, Grant S.

Mol Cancer Ther. 2005 Nov;4(11):1772-85.

18.

Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.

Dasmahapatra G, Almenara JA, Grant S.

Mol Pharmacol. 2006 Jan;69(1):288-98. Epub 2005 Oct 11. Retraction in: Mol Pharmacol. 2019 Apr;95(4):335.

PMID:
16219908
19.

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.

Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P, Grant S.

Mol Pharmacol. 2006 Jan;69(1):216-25. Epub 2005 Sep 27. Retraction in: Mol Pharmacol. 2019 Apr;95(4):336.

PMID:
16189296
20.

Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.

Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S.

Leukemia. 2004 Nov;18(11):1780-8.

PMID:
15385934
25.

A new death domain associated with gestational trophoblastic diseases induces apoptosis in distinct cell types.

Dumur CI, Almenara JA, Durand S, Flury A, Koritschoner NP, Patrito LC.

Int J Oncol. 2001 Dec;19(6):1161-7.

PMID:
11713585

Supplemental Content

Loading ...
Support Center